We combine bioinformatic data analysis in patients with cutting-edge molecular biology and in vivo CRISPR modeling to understand and treat HUMAN LIVER DISEASE, including  FIBROSIS and MASLD ('fatty liver).

A key long-term is to find combination treatments that prolong survival in patients with LIVER CANCER (HCC and CCA)

Representative papers

1. Sugimoto A, Saito Y, Wang G, et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature. 2025;640(8059):752-761. doi:10.1038/s41586-025-08677-w

2. Saito Y, Yin D, Kubota N, et al. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology. 2023;164(7):1279-1292. doi:10.1053/j.gastro.2023.02.043